Title: Dalbavancin
CAS Registry Number: 171500-79-1
CAS Name: 5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methyl-1-oxoundecyl)amino]-b-D-glucopyranuronosyl]-38-[[[3-(dimethylamino)propyl]amino]carbonyl]-42-O-a-D-mannopyranosyl-N15-methylristomycin A aglycone
Manufacturers' Codes: BI-397; MDL-63397
Molecular Formula: C88H100Cl2N10O28
Molecular Weight: 1816.69
Percent Composition: C 58.18%, H 5.55%, Cl 3.90%, N 7.71%, O 24.66%
Literature References: Semisynthetic glycopeptide antibiotic derived from the natural glycopeptide, A-40926. Structurally related to teicoplanin, q.v. Prepn: A. Malabarba et al., J. Antibiot. 48, 869 (1995). In vitro antibacterial activity: J. M. Streit et al., Diagn. Microbiol. Infect. Dis. 48, 137 (2004). Clinical pharmacology: A. Leighton et al., Antimicrob. Agents Chemother. 48, 940 (2004). Clinical evaluation in skin and soft-tissue infections: E. Seltzer et al., Clin. Infect. Dis. 37, 1298 (2003); in catheter-related bloodstream infections: I. Raad et al., ibid. 40, 374 (2005). Series of articles on development and antibacterial activity: J. Antimicrob. Chemother. 55, Suppl. S2, ii5-ii35 (2005).
Therap-Cat: Antibacterial.
Keywords: Antibacterial (Antibiotics); Polypeptides.
Dalfopristin D-Allose Dalteparin Daltroban D-Altrose

Clinical data
Legal status  ?
Routes Intravenous
CAS number 171500-79-1 YesY
ATC code J01XA04
PubChem CID 16134410
ChemSpider 23340937 N
Chemical data
Formula C88H100Cl2N10O28 
Mol. mass 1755.634 g/mol
 N (what is this?)  (verify)

Dalbavancin (INN, trade name Zeven) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).[1]

Dalbavancin (BI397) is a novel semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.[2]

It possesses in vitro activity against a variety of Gram-positive pathogens[3][4] including MRSA and MRSE.[5] It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.[6]